We are happy to announce a contract for new drug development was awarded to WuXi App Tec. WuXi is a global company that shares our mission. Their open access platform of manufacturing services advances discoveries and delivers groundbreaking treatments to patients. Their vision is “every drug can be made and every disease can be treated”. WuXi has over 20 years experience in synthetic chemistry services. What makes our visions converge is that along with small molecule drug R&D and manufacturing capabilities, they move quickly. Our shared goal is that our new molecule will be a drug ready for safety testing in ALS patients by the end of 2022. The unfortunate climate of the global pandemic of 2019-2021 didn’t slow them down and we anticipate our project to move quickly. Welcome WuXi to NDR’s team!
top of page
Recent Posts
See AllIndiana University researcher Chandler Walker, Ph.D., developed a stem cell-based secretome therapy that influences both the central and peripheral components of Amyotrophic Lateral Sclerosis (ALS) pa
18
The preprint manuscript Assessment of levamisole HCl and thymosin α1 in two mouse models of amyotrophic lateral sclerosis by David R Borchelt (Department of Neuroscience, University of Florida, Colle
23
NDR congratulates Dr. Chandler Walker, Associate Professor in the department of Biomedical Sciences and Comprehensive Care, Indiana University School of Dentistry, on the acceptance of his paper repor
12
bottom of page